Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters.

Lu X, Gibbs JS, Hickman HD, David A, Dolan BP, Jin Y, Kranz DM, Bennink JR, Yewdell JW, Varma R.

Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15407-12. Epub 2012 Sep 4.

2.
3.

Viral and bacterial minigene products are presented by MHC class I molecules with similar efficiencies.

Wolf BJ, Princiotta MF.

Mol Immunol. 2011 Jan;48(4):463-71. doi: 10.1016/j.molimm.2010.10.002. Epub 2010 Nov 10.

PMID:
21067810
4.

Endogenous presentation of a nascent antigenic epitope to CD8+ CTL is more efficient than exogenous presentation.

Hahn YS, Hahn CS, Braciale TJ.

Immunol Cell Biol. 1996 Oct;74(5):394-400.

PMID:
8912001
5.

Targeting HIV-1 Gag into the defective ribosomal product pathway enhances MHC class I antigen presentation and CD8+ T cell activation.

Goldwich A, Hahn SS, Schreiber S, Meier S, Kämpgen E, Wagner R, Lutz MB, Schubert U.

J Immunol. 2008 Jan 1;180(1):372-82.

6.
7.

Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules.

Ge Q, Stone JD, Thompson MT, Cochran JR, Rushe M, Eisen HN, Chen J, Stern LJ.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13729-34. Epub 2002 Oct 8.

8.

The nonclassical MHC class I molecule Qa-1 forms unstable peptide complexes.

Kambayashi T, Kraft-Leavy JR, Dauner JG, Sullivan BA, Laur O, Jensen PE.

J Immunol. 2004 Feb 1;172(3):1661-9.

9.

Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.

Tewalt EF, Grant JM, Granger EL, Palmer DC, Heuss ND, Gregerson DS, Restifo NP, Norbury CC.

PLoS Pathog. 2009 May;5(5):e1000457. doi: 10.1371/journal.ppat.1000457. Epub 2009 May 29.

10.

Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.

Wälchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O, Olweus J, Gregers TF.

Eur J Immunol. 2014 Mar;44(3):774-84. doi: 10.1002/eji.201343671. Epub 2013 Dec 27.

11.

Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.

Housseau F, Bright RK, Simonis T, Nishimura MI, Topalian SL.

J Immunol. 1999 Dec 1;163(11):6330-7.

12.

mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity.

Cafri G, Sharbi-Yunger A, Tzehoval E, Alteber Z, Gross T, Vadai E, Margalit A, Gross G, Eisenbach L.

Mol Ther. 2015 Aug;23(8):1391-1400. doi: 10.1038/mt.2015.90. Epub 2015 May 22.

13.
15.

Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection.

Wakim LM, Bevan MJ.

Nature. 2011 Mar 31;471(7340):629-32. doi: 10.1038/nature09863.

16.

The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design.

Sijts A, Zaiss D, Kloetzel PM.

Curr Mol Med. 2001 Dec;1(6):665-76. Review.

PMID:
11899255
17.

Generating MHC class I ligands from viral gene products.

Yewdell J, Antón LC, Bacik I, Schubert U, Snyder HL, Bennink JR.

Immunol Rev. 1999 Dec;172:97-108. Review.

PMID:
10631940
19.

Defective ribosomal products are the major source of antigenic peptides endogenously generated from influenza A virus neuraminidase.

Dolan BP, Li L, Takeda K, Bennink JR, Yewdell JW.

J Immunol. 2010 Feb 1;184(3):1419-24. doi: 10.4049/jimmunol.0901907. Epub 2009 Dec 28.

Supplemental Content

Support Center